Search clinical trials for: CYT-0851

Total 6375 results

Cyteir Therapeutics, Inc.

Active, not recruiting

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Soft Tissue Sarcoma | Follicular Lymphoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Multiple Myeloma | Pancreatic Cancer | Ovarian Cancer | Mantle Cell Lymphoma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | DLBCL | Non-hodgkin Lymphoma | Malignancy | CLL

United States
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
GV20 Therapeutics

Recruiting

A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Cholangiocarcinoma | Non-small Cell Lung Cancer | Endometrial Carcinoma | Head and Neck Carcinoma | Cutaneous Melanoma | Solid Tumor, Adult | Refractory Cancer | Adenocarcinoma of the Rectum | Bladder Urothelial Carcinoma | Adenocarcinoma of the Colon

United States
Genentech, Inc.

Terminated

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Brazil, Argentina, Mexico, Chile, United Kingdom
CK Regeon Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

Healthy

Korea, Republic of
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

United States, Australia
Genentech, Inc.

Completed

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Urticaria

United States, Germany, Canada
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Ablynx

Terminated

First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4

Healthy Volunteers

Netherlands
Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-0551 in Patients With Systemic Sclerosis

Systemic Sclerosis

Japan
Genentech, Inc.

Terminated

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

Urticaria

United States
Genentech, Inc.

Completed

A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Argentina, Brazil, Mexico, United Kingdom, Chile, Germany
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Novo Nordisk A/S

Completed

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

United Kingdom, Romania, Poland, Denmark, Czech Republic, Hungary
Oramed, Ltd.
Integrium

Completed

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

Renal Anemia in Non-dialysis Chronic Kidney Disease

China
The University of Texas Health Science Center at...
Oramed, Ltd.

Completed

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

Type 1 Diabetes

United States
Shanghai Kechow Pharma, Inc.

Recruiting

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 | Plexiform Neurofibromas

China
Kechow Pharma, Inc.

Completed

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

Solid Tumor, Adult

United States
Shanghai Kechow Pharma, Inc.

Completed

Study of HL-085 in NRAS Mutant Advanced Melanoma

Melanoma

China
Shanghai Kechow Pharma, Inc.

Completed

HL-085 in NRAS-mutated Advanced Melanoma

Melanoma

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Renal Impairment

Germany
ENA Respiratory Pty Ltd

Completed

INNA-051 Influenza Challenge Study

Influenza Prophylaxis

United Kingdom
Akros Pharma Inc.

Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Skin Diseases | Plaque Psoriasis

United States, Canada
Akros Pharma Inc.

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis (MOVE-RA)

Rheumatoid Arthritis

Ukraine, United States, Argentina, Bulgaria, Romania, Peru, Russian Federation, Mexico, Colombia, Poland
ENA Respiratory Pty Ltd

Withdrawn

Intranasal INNA-051 for Prevention of COVID-19 in Adults

COVID-19 Pandemic
University of Sao Paulo General Hospital

Unknown

Efficacy of Compassion Focused Therapy in Group for Posttraumatic Stress Disorder (GCFT-PTSD)

PTSD

Brazil
King Hamad University Hospital, Bahrain
Royal College of Surgeons in Ireland - Medical University of Bahrain; Oramed...

Not yet recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Pardes Biosciences, Inc.

Completed

Study of PBI-0451 in Healthy Subjects.

Covid19

New Zealand
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Hadassah Medical Organization
Oramed Pharmaceutical Inc.

Completed

Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients

Brittle Type I Diabetes Mellitus

Israel
Light Chain Bioscience - Novimmune SA

Completed

NI-0801 in Allergic Contact Dermatitis

Allergic Contact Dermatitis
Cullinan Oncology Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Singapore, Hong Kong, Netherlands, Japan, China, Korea, Republic of
Allegheny Singer Research Institute (also known...
National Institute of Mental Health (NIMH); University of Medicine and Dentistry...

Completed

Treatment of Post-Traumatic Stress Disorder (PTSD) in Sexually Abused Children

Stress Disorders, Post-Traumatic

United States
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom; Onyx Therapeutics, Inc.

Completed

Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (ONX-0801)

Solid Tumours

United Kingdom
Novo Nordisk A/S

Completed

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Inflammation | Healthy | Rheumatoid Arthritis | Systemic Lupus Erythematosus

Netherlands
Novo Nordisk A/S

Withdrawn

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

United States
Shanghai Kechow Pharma, Inc.

Terminated

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Healthy Subjects

United Kingdom
Oramed, Ltd.
Integrium

Terminated

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Oramed, Ltd.
Integrium

Completed

A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

Type 1 Diabetes

United States
Oramed, Ltd.
Integrium

Completed

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus Type 2

United States
AbbVie

Completed

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Undifferentiated Pleomorphic Sarcoma | Carcinoma of the Breast

United States, France, Spain

Search clinical trials for: CYT-0851

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations